Carnegie Investment Counsel Invests $12.37 Million in Hologic, Inc. (NASDAQ:HOLX)

Carnegie Investment Counsel acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 200,255 shares of the medical equipment provider's stock, valued at approximately $12,370,000. Carnegie Investment Counsel owned 0.09% of Hologic at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Allworth Financial LP lifted its position in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Hologic in the 1st quarter valued at about $42,000. Larson Financial Group LLC boosted its holdings in Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after buying an additional 722 shares during the last quarter. Raiffeisen Bank International AG acquired a new stake in Hologic in the 4th quarter worth about $49,000. Finally, West Financial Advisors LLC purchased a new stake in Hologic during the 1st quarter worth approximately $50,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director owned 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.88% of the company's stock.

Hologic Trading Up 0.6%

Shares of NASDAQ HOLX traded up $0.40 during midday trading on Friday, reaching $66.50. 1,116,538 shares of the stock were exchanged, compared to its average volume of 1,795,352. The stock has a 50 day moving average price of $63.33 and a 200-day moving average price of $63.00. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $14.82 billion, a P/E ratio of 28.06, a P/E/G ratio of 2.42 and a beta of 0.55. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. Hologic's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.03 EPS. Equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on HOLX. Morgan Stanley decreased their price objective on Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Stephens dropped their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Mizuho increased their price target on shares of Hologic from $65.00 to $70.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Finally, Evercore ISI upped their price target on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $77.33.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.